Bristol Myers Squibb (NYSE: BMY) has added a new indication to the US label for Opdivo (nivolumab) plus Yervoy (ipilimumab), to treat hepatocellular carcinoma (HCC).
The approval relates to people who have been previously treated with sorafenib, which is marketed as Nexavar by German pharma major Bayer (BAYN: DE).
The accelerated approval, which is contingent upon confirmatory trials, is based on the overall response rate and duration of response seen in the Phase I/II CheckMate-040 trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze